Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01050673
Other study ID # CE/030/VJT
Secondary ID
Status Completed
Phase N/A
First received January 13, 2010
Last updated February 12, 2018
Start date November 2007
Est. completion date September 2011

Study information

Verified date February 2018
Source Smith & Nephew, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is increasingly recognised that the debridement of devitalised, bacterially contaminated or senescent tissue is an essential component of the effective treatment of delayed healing wounds.

Whilst surgical debridement procedures have conventionally been performed with scalpels and other sharp instrumentation, alternative techniques such as the VERSAJET Hydrosurgery System are becoming more widespread.

To increase the adoption of this new technology, it is essential that clinical improvements are assessed alongside the potential impact on the costs of debridement and the net financial impact on the hospital.

It is hypothesised that a decrease in the time to achieve stable wound closure will not only lead to a patient benefit, but also a potential reduction in the cost of treatment due to e.g. repeat procedures, longer hospital stay, infection etc. The purpose of this study is to investigate the difference in time to closure of wounds surgically excised with VERSAJET Hydrosurgery System and those surgically excised using conventional operating room techniques.


Description:

It is increasingly recognised that the debridement of devitalised, bacterially contaminated or senescent tissue is an essential component of the effective treatment of delayed healing wounds. Whilst passive autolytic or enzymatic debridement procedures have their place, where patients are unable to tolerate any surgical procedure, the judicious use of surgical debridement to rapidly remove necrotic, contaminated tissue and slough has been shown to offer many advantages in returning a wound to a healing trajectory.

Whilst surgical debridement procedures have conventionally been performed with scalpels and other sharp instrumentation, alternative techniques such as the VERSAJET Hydrosurgery System are becoming more widespread.

To increase the adoption of this new technology, it is essential that clinical improvements are assessed alongside the potential impact on the costs of debridement and the net financial impact on the hospital. In fiscal year 2004, there were more than 57,000 discharges under DRG code 217 ('wound debridement and skin graft except hand) in the United States. Mean length of stay (all payers) was 11 days and mean charges were $52,800. In 2005, Medicare funded 15,800 discharges under this code. Average charges for these patients were $56,500 and average reimbursement was $18,2654. In this context it is particularly important that the potential patient benefit and cost impact of new technology is fully assessed.

It is hypothesised that a decrease in the time to achieve stable wound closure will not only lead to a patient benefit, but also a potential reduction in the cost of treatment due to e.g. repeat procedures, longer hospital stay, infection etc. The purpose of this study is to investigate the difference in time to closure of wounds surgically excised with VERSAJET Hydrosurgery System and those surgically excised using conventional operating room techniques.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date September 2011
Est. primary completion date June 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients aged 18 years and older

- Male, and female patients (provided they are not pregnant and if of reproductive age are using contraception)

- Patients with a delayed healing traumatic wound or chronic cutaneous defect of 30 days or more in duration, or a delayed healing dehisced incision that requires excision to remove necrotic or infected tissue

- Patients who are deemed to require closure by primary intention or definitive cover with an autologous split-thickness skin graft (STSG) or flap

- Patients who are hospital in-patients, or will be an in-patient for the period of 1st excision to closure

- Patients deemed suitable for debridement with both VERSAJET Hydrosurgery System and conventional operating room techniques

- Patients undergoing surgical excision of their reference wound in the operating room (OR)

- Patients able to understand the evaluation and willing to consent to the evaluation

Exclusion Criteria:

- Patients who have previously undergone surgical excision of the reference wound by the Principal Investigator in the last 30 days

- Patients with coagulopathy (including those with haemophilia)

- Patients with vasculitis, non-reconstructive peripheral vascular disease, pyoderma granulosa, renal failure or lymphoedema

- Patients with irradiated, burn or ischaemic wounds

- Patients with a BMI >35

- Patients deemed to require a staged procedure, with hospital discharge occurring between procedures

- Patients deemed to require biological dressings / skin substitutes

- Patients for whom wound healing by secondary intention is deemed necessary

- Patients who have been treated with systemic immunosuppressants (including corticosteroids), or cytotoxic chemotherapy in the last 30 days, or who are anticipated to require such medications during the course of the study

- Patients known to have Acquired Immunodeficiency Syndrome (AIDS) or known to be infected with Human Immunodeficiency Virus (HIV)

- Patients with a known history of poor compliance with medical treatment

- Patients who have participated in this evaluation previously or who are currently participating in another clinical study

Study Design


Intervention

Device:
VERSAJET
Hydro-surgery debridement
Procedure:
Scalpel or blade
Conventional Surgical Debridement

Locations

Country Name City State
United States Northwestern University Feinberg School of Medicine Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Smith & Nephew, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (2)

Attinger CE, Janis JE, Steinberg J, Schwartz J, Al-Attar A, Couch K. Clinical approach to wounds: débridement and wound bed preparation including the use of dressings and wound-healing adjuvants. Plast Reconstr Surg. 2006 Jun;117(7 Suppl):72S-109S. Review. — View Citation

Steed DL, Donohoe D, Webster MW, Lindsley L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg. 1996 Jul;183(1):61-4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Difference in Time to Closure Between Wounds Surgically Excised With VERSAJETâ„¢ Hydrosurgery System and Those Surgically Excised Using Conventional Operating Room Techniques. 28 days plus 6 week follow-up
Secondary Time of Actual Excision Procedure 28 days
Secondary Cost Per Operative Procedure 28 days
Secondary Cost of Reference Wound-related Surgical Procedures to Achieve Closure 28 days
Secondary Quantitative Bacteriology From Standardised Tissue Biopsies Pre- /Post- 1st Excision & Pre-closure 28 days
Secondary Percentage of Patients Achieving Stable Closure Within Study Period 28 days
Secondary Length of Hospital Stay (1st Excision to Discharge (Days)) 28 days
Secondary Number of Patient's With Wound-related Readmissions 28 days and 6 week follow up
Secondary Number of Patient's With Serious Adverse Events and Relationship to Device 28 days
See also
  Status Clinical Trial Phase
Terminated NCT00654641 - Prevention of Wound Complications After Cesarean Delivery in Obese Women Utilizing Negative Pressure Wound Therapy N/A
Recruiting NCT04920253 - Real World Evidence With the Debritom+ TM Novel Micro Water Jet Technology at a Single Wound Center N/A
Terminated NCT01679678 - A Study, Performed in Subjects With Post Traumatic-post Surgical ,Venus Insufficiency and Diabetic Hard to Heal/Chronic Wounds, to Evaluate the Safety and Efficacy of PolyHeal-2 Versus PolyHeal in Once Daily Regimen Phase 2
Terminated NCT01083472 - Repair of Challenging Abdominal Wall Defects: Strattice(TM) TM in Abdominal Wall Repair (StAR) Phase 4
Terminated NCT00260494 - Acupuncture and Post-Surgical Wound Healing N/A
Active, not recruiting NCT04257097 - Reinforced PTFE Meshes Versus Customized Titanium Meshes N/A
Not yet recruiting NCT04894604 - A Safety and Performance PMCF Investigation of the Avance® Solo NPWT System in Surgically Closed Incisions N/A
Completed NCT03293862 - Prevention of Fascial Dehiscence With Prophylactic Onlay Mesh in Emergency Laparotomies N/A
Completed NCT01658163 - Use of 2-octyl-cyanoacrylate Together With a Self-adhering Mesh N/A
Completed NCT05716490 - Optimizing Closed Incision Negative Pressure Wound Therapy in Emergency Laparotomy N/A
Enrolling by invitation NCT02581904 - Prevena Vascular Groin Wound Study Phase 4
Recruiting NCT02322554 - Cellular and Tissue Based Therapy Registry
Recruiting NCT02280733 - A Real World, Observational Registry of Chronic Wounds and Ulcers
Recruiting NCT02467998 - Negative Pressure Wound Therapy Registry
Completed NCT02453165 - Vaginal Cuff Dehiscence Following Total Laparoscopic Hysterectomy: Laparoscopic vs. Transvaginal Cuff Closure N/A
Completed NCT04286334 - Three-dimensional Bone Regeneration Using Custom-made Meshes With and Without Collagen Membrane N/A
Completed NCT02879487 - Vaginal Cuff Dehiscence at Total Laparoscopic Hysterectomy N/A
Completed NCT02565043 - The Clinical Efficacy of RENASYS TOUCH NPWT System in the Management of Acute, Sub-acute and Chronic Wounds N/A
Terminated NCT01693484 - Application of Indocyanine Green Angiography for Closed Operative Calcaneus Fractures Phase 2/Phase 3